Thayer-Martin Agar (Modified): Composition, Principle, Uses, and Colony Characteristics of Neisseria

A 24-year-old man presents to a sexual health clinic with urethral discharge and dysuria. The clinician performs a urethral swab. Two things happen simultaneously in the laboratory: a Gram stain of the discharge is examined for Gram-negative intracellular diplococci, and the swab is inoculated directly onto a warm plate of Modified Thayer-Martin agar and placed immediately into a CO2-enriched atmosphere.

The reason for this specific medium — and the urgency of immediate inoculation before the swab dries — reflects the biological nature of Neisseria gonorrhoeae. It is one of the most fastidious organisms in clinical bacteriology: it cannot survive drying, cannot tolerate room temperature for more than a few minutes on a swab, requires specific growth factors absent from standard media, and dies if incubated in air without elevated CO2. Modified Thayer-Martin agar was designed specifically to meet these requirements while simultaneously suppressing the commensal organisms that would otherwise overgrow it.

Thayer-Martin agar is a selective medium used for the isolation of gonococci (Neisseria gonorrhoeae) from specimens containing a mixed flora of bacteria and/or fungi e.g. urogenital specimen. Modified Thayer-Martin (MTM) agar is a GC agar base containing vancomycin, colistin, nystatin, and trimethoprim lactate (VCNT). Selective isolation of Neisseria gonorrhoeae is achieved with suppression of most other gram-negative diplococci, gram-negative bacilli, gram-positive organisms, and yeast.

Figure: Neisseria gonorrhoeae (Image source: http://www.microbiologyinpictures.com/)

Principle

Why N. gonorrhoeae requires a specialised medium:

Neisseria gonorrhoeae is an obligate human pathogen with complex nutritional requirements that standard bacteriological media cannot meet:

• It requires hemin (X factor) — the iron-containing porphyrin used in aerobic metabolism
• It requires NAD (V factor) — the coenzyme essential for multiple metabolic pathways
• It is inhibited by toxic fatty acids present in many agar bases, including standard blood agar
• It is an obligate aerobe with capnophilic growth requirements — it needs elevated CO2 (5–10%) for optimal growth
• It is extremely sensitive to desiccation and temperature fluctuations — specimens must be inoculated immediately

Modified Thayer-Martin agar addresses all of these requirements in its formulation:

The VCNT selectivity mechanism — why each antibiotic is chosen:

The four antibiotics in Modified Thayer-Martin agar are selected to create a broad spectrum of suppression while specifically sparing N. gonorrhoeae:

Key exam point: Gonococci survive colistin — an agent that inhibits most Gram-negative organisms — due to specific outer membrane modifications. This intrinsic colistin resistance is one of the few characteristics that distinguishes N. gonorrhoeae and N. meningitidis from other Gram-negative organisms and is the basis for the selectivity of Thayer-Martin medium.

Thayer-Martin vs Modified Thayer-Martin: The original Thayer-Martin medium (1966) contained vancomycin, colistin, and nystatin (VCN). The Modified Thayer-Martin (MTM) formulation added trimethoprim lactate to suppress Proteus swarming, which was a recognised problem with the original medium in genital specimens. MTM is now the standard formulation used in most clinical laboratories; the terms "Thayer-Martin" and "Modified Thayer-Martin" are often used interchangeably in clinical practice, though strictly MTM refers to the four-antibiotic formulation.

Composition of Modified Thayer-Martin Agar

MTM agar is assembled from three components:

Component 1 — GC Agar Base (per liter)

Component 2 — 2% Haemoglobin Solution Provides hemin (X factor) in bioavailable form. Sheep or bovine haemoglobin is used. Autoclaved separately to prevent lysis products from interfering with antibiotic activity.

Component 3 — Growth Supplement (IsoVitaleX or equivalent) Provides NAD (V factor), thiamine pyrophosphate, glutamine, adenine, ferric nitrate, and other growth factors required for Neisseria growth. Added aseptically after cooling to 50°C — heat-labile components would be destroyed by autoclaving.

Selective antibiotics (added aseptically to cooled base): Vancomycin 3 µg/mL, Colistin 7.5 µg/mL, Nystatin 12.5 units/mL, Trimethoprim lactate 5 µg/mL

Final pH: 7.2 ± 0.2 at 25°C

Uses of Modified Thayer-Martin Agar

1. Primary isolation of Neisseria gonorrhoeae from genital specimens MTM is inoculated directly at the point of specimen collection (or immediately after transport) for:

• Urethral swabs (men with urethral discharge; asymptomatic urethral screening)
• Endocervical swabs (women; symptomatic discharge, routine screening, sexual assault examination)
• Vaginal swabs (including self-collected swabs in women)
• Rectal swabs (men who have sex with men; rectal gonorrhoea)
• Pharyngeal swabs (oro-pharyngeal gonorrhoea — increasing in prevalence)

2. Conjunctival specimens Neonatal ophthalmia neonatorum caused by N. gonorrhoeae is a sight-threatening emergency. Conjunctival swabs from neonates born to mothers with untreated gonorrhoea are inoculated onto MTM.

3. Neisseria meningitidis isolation from non-sterile site specimens While N. meningitidis is typically isolated from blood and CSF (sterile sites, where MTM is not needed), nasopharyngeal specimens for meningococcal carrier screening use MTM to recover N. meningitidis from heavily colonised mucosa.

4. Gonorrhoea surveillance programmes MTM is the medium of choice for gonorrhoea surveillance cultures in sexual health clinics, contact tracing investigations, and antibiotic resistance surveillance programmes.

Important specimen handling note: N. gonorrhoeae is extremely sensitive to drying, cold temperatures, and delay. Swabs should be inoculated onto MTM immediately at the point of collection if possible. If transport is unavoidable, use a transport system with CO2 (e.g., JEMBEC plates — MTM plates in a CO2-generating transport system). Swabs left in standard Stuart's or Amies transport medium for more than 6 hours show significantly reduced recovery.

Media preparation

1. Suspend 7.2 g of GC agar base in 100 ml distilled water in a flask. Mix thoroughly, heat with frequent agitation, and bring to a boil for 1 minute to completely dissolve the powder.
2. Autoclave the flask at 121°C for 15 minutes.
3. Cool to 50°C in a water bath.
4. Add 100 ml of warm distilled water to 2 g of soluble hemoglobin powder. Mix the powder with 5-10 ml of distilled water until a smooth paste is achieved. Gradually add the balance of water until the solution is homogenous. Continually stir the solution during the addition of water.  Alternatively, 100 ml ready-made 2% sterile hemoglobin solution, warmed to 50°C can be used.
5. Autoclave the solution at 121°C for 15 minutes. Cool to 50°C in a water bath.
6. Reconstitute lyophilized growth supplement containing NAD and hemin by aseptically transferring 10 ml of the accompanying diluent with a sterile needle and syringe. Shake to assure complete solution. After reconstitution, use immediately or store at 4°C and use within 2 weeks.
7. Aseptically add 100 ml sterile hemoglobin solution and growth supplement to 100 ml of the GC agar base solution. Mix gently, but thoroughly, to avoid air bubbles in the agar.
8. To the agar base solution, add the following ingredients: 3.0 µg/ml vancomycin 7.5 µg/ml colistin 12.5 units/ml nystatin 5.0 µg/ml trimethoprim lactate
9. Dispense 20 ml into 15×100 mm Petri dishes. Allow the media to solidify and condensation to dry.
10. Place the plates in sterile plastic bags and store them at 4°C until use.

Culture and Isolation

1. Specimen (urethral or endocervical) is directly inoculated in the culture plates (swabs with plastic or wire shafts and rayon, Dacron, or calcium alginate tips is used to collect the specimen for the culture of gonococci).
2. The inoculated culture plate should be promptly placed into a CO2-enriched (3%- 10%) environment and incubated at 35º-37ºC.
3. Small opaque, grayish-white to colorless, raised, glistening and smooth colonies are seen.

Quality control

• Grow N. meningitidis QC strain for 18-24 hours on MTM at 35-37°C with ~5% CO2 (or in a candle jar).
• Observe the MTM for specific colony morphology.
• As a sterility test, incubate an uninoculated plate for 48 hours at 35-37°C with ~5% CO2 (or in a candle jar).

Colony Characteristics of Neisseria on Modified Thayer-Martin Agar

N. gonorrhoeae exhibits colony type variation (T1–T4) based on the presence and density of pili and outer membrane proteins. This variation is visible on MTM agar and has clinical significance:

Practical note: Fresh clinical isolates typically produce T1 and T2 colonies (small, raised, glistening). After 2–3 laboratory subcultures, T3 and T4 variants emerge. For antibiotic susceptibility testing and characterisation, always use first- or second-passage cultures to ensure you are working with piliated, virulent strains representative of the clinical isolate.

General colony description on MTM: Colonies appear at 24–48 hours. Typical gonococcal colonies are: 0.5–1 mm diameter, grey-white to colourless, raised, convex, smooth, glistening surface, entire margin. They are oxidase-positive — a drop of tetramethyl-p-phenylenediamine reagent turns the colony dark purple within 10 seconds, confirming oxidase positivity.

Distinguishing N. gonorrhoeae from N. meningitidis on MTM:

The maltose rule: Both N. gonorrhoeae and N. meningitidis ferment glucose. Only N. meningitidis ferments maltose. This single sugar utilisation test is the most reliable rapid method for differentiating the two organisms after growth on MTM — critical when determining whether a positive Neisseria culture from a genital specimen is a gonococcal or meningococcal isolate.

Choosing Neisseria Isolation Medium: MTM vs NYC vs Martin-Lewis

Three selective media are commonly used for Neisseria gonorrhoeae isolation. Understanding the differences is important for laboratories choosing their medium and for students encountering all three in references.

Practical note for Nepal and similar settings: Modified Thayer-Martin is the standard and most widely available medium. NYC medium has the advantage of supporting Ureaplasma and Mycoplasma growth in addition to gonococci — useful in STI clinics that want a single plate for multiple fastidious urogenital pathogens. Martin-Lewis agar substitutes anisomycin for nystatin, which some practitioners prefer when nystatin batch variability is a concern.

How to Remember

MTM = GC base + haemoglobin + supplement + VCNT

Four components, each answering one question:

• GC base — Why doesn't blood agar work? Because its peptone base contains toxic fatty acids that inhibit N. gonorrhoeae; corn starch in GC base neutralises them.
• Haemoglobin — Provides hemin (X factor); must be autoclaved separately to avoid antibiotic interference.
• Growth supplement — Provides NAD (V factor) and other heat-labile growth factors; added aseptically after cooling.
• VCNT — Four targeted antibiotics, each suppressing one category of competing flora; gonococci survive all four.

The VCNT mnemonic — what each kills:

Vancomycin kills Gram-positives (V for Very-positive-killing) Colistin kills Gram-negatives (including commensal Neisseria — gonococci are the exception) Nystatin kills fungi Trimethoprim stops Proteus swarming (T for Trimethoprim → Proteus)

The clinical anchor — immediate inoculation: N. gonorrhoeae is so fragile that the standard teaching point is: "inoculate the plate before the patient leaves the room." This is not hyperbole — the organism dies within minutes on a dry swab. Every step in the MTM protocol (pre-warming the plate, CO2 incubation, JEMBEC transport systems) exists because of this extreme fragility.

Maltose as the key differentiator: After any Neisseria colony grows on MTM, the single most important next test is maltose fermentation. N. gonorrhoeae does not ferment maltose; N. meningitidis does. This distinction matters clinically — finding N. meningitidis in a genital specimen in a young adult has entirely different treatment and contact tracing implications than finding N. gonorrhoeae.

References

1. Tille, P. M. (2017). Bailey and Scott's Diagnostic Microbiology (14th ed.). Elsevier.
2. World Health Organization. (2016). WHO Guidelines for the Treatment of Neisseria gonorrhoeae. Geneva: WHO.
3. Greenwood, J. R., Voss, J., Smith, R. F., Wallace, H., Peter, C., Nachtigall, M., Maier, T., Wilber, J., & Butsumyo, A. (1986). Comparative evaluation of New York City and modified Thayer-Martin media for isolation of Neisseria gonorrhoeae. Journal of clinical microbiology, 24(6), 1111–1112.
4. Morse, S. A., & Lysko, P. G. (1985). Gonococcal colony types. Infection and Immunity, 49(2), 341–350.